nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—Angioedema—Methylprednisolone—ankylosing spondylitis	0.00253	0.00253	CcSEcCtD
Fosaprepitant—Abdominal discomfort—Methotrexate—ankylosing spondylitis	0.00252	0.00252	CcSEcCtD
Fosaprepitant—Erythema—Dexamethasone—ankylosing spondylitis	0.00252	0.00252	CcSEcCtD
Fosaprepitant—Erythema—Betamethasone—ankylosing spondylitis	0.00252	0.00252	CcSEcCtD
Fosaprepitant—Malaise—Triamcinolone—ankylosing spondylitis	0.0025	0.0025	CcSEcCtD
Fosaprepitant—Malaise—Methylprednisolone—ankylosing spondylitis	0.0025	0.0025	CcSEcCtD
Fosaprepitant—Syncope—Triamcinolone—ankylosing spondylitis	0.00249	0.00249	CcSEcCtD
Fosaprepitant—Syncope—Methylprednisolone—ankylosing spondylitis	0.00248	0.00248	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.00248	0.00248	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.00246	0.00246	CcSEcCtD
Fosaprepitant—Oedema—Prednisolone—ankylosing spondylitis	0.00246	0.00246	CcSEcCtD
Fosaprepitant—Dysuria—Methotrexate—ankylosing spondylitis	0.00246	0.00246	CcSEcCtD
Fosaprepitant—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.00244	0.00244	CcSEcCtD
Fosaprepitant—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.00243	0.00243	CcSEcCtD
Fosaprepitant—Shock—Prednisolone—ankylosing spondylitis	0.00242	0.00242	CcSEcCtD
Fosaprepitant—Cough—Triamcinolone—ankylosing spondylitis	0.00242	0.00242	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Methotrexate—ankylosing spondylitis	0.0024	0.0024	CcSEcCtD
Fosaprepitant—Hypertension—Triamcinolone—ankylosing spondylitis	0.0024	0.0024	CcSEcCtD
Fosaprepitant—Hypertension—Methylprednisolone—ankylosing spondylitis	0.00239	0.00239	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.00238	0.00238	CcSEcCtD
Fosaprepitant—Eye disorder—Prednisone—ankylosing spondylitis	0.00235	0.00235	CcSEcCtD
Fosaprepitant—Anxiety—Methylprednisolone—ankylosing spondylitis	0.00235	0.00235	CcSEcCtD
Fosaprepitant—Infestation NOS—Methotrexate—ankylosing spondylitis	0.00235	0.00235	CcSEcCtD
Fosaprepitant—Infestation—Methotrexate—ankylosing spondylitis	0.00235	0.00235	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.00234	0.00234	CcSEcCtD
Fosaprepitant—Flushing—Prednisone—ankylosing spondylitis	0.00234	0.00234	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Dexamethasone—ankylosing spondylitis	0.00234	0.00234	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Betamethasone—ankylosing spondylitis	0.00234	0.00234	CcSEcCtD
Fosaprepitant—Discomfort—Triamcinolone—ankylosing spondylitis	0.00233	0.00233	CcSEcCtD
Fosaprepitant—Discomfort—Methylprednisolone—ankylosing spondylitis	0.00233	0.00233	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	0.00232	0.00232	CcSEcCtD
Fosaprepitant—Dry mouth—Triamcinolone—ankylosing spondylitis	0.00231	0.00231	CcSEcCtD
Fosaprepitant—Angioedema—Dexamethasone—ankylosing spondylitis	0.0023	0.0023	CcSEcCtD
Fosaprepitant—Angioedema—Betamethasone—ankylosing spondylitis	0.0023	0.0023	CcSEcCtD
Fosaprepitant—Stomatitis—Methotrexate—ankylosing spondylitis	0.00229	0.00229	CcSEcCtD
Fosaprepitant—Angiopathy—Prednisone—ankylosing spondylitis	0.00229	0.00229	CcSEcCtD
Fosaprepitant—Conjunctivitis—Methotrexate—ankylosing spondylitis	0.00228	0.00228	CcSEcCtD
Fosaprepitant—Immune system disorder—Prednisone—ankylosing spondylitis	0.00228	0.00228	CcSEcCtD
Fosaprepitant—Malaise—Dexamethasone—ankylosing spondylitis	0.00227	0.00227	CcSEcCtD
Fosaprepitant—Malaise—Betamethasone—ankylosing spondylitis	0.00227	0.00227	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.00226	0.00226	CcSEcCtD
Fosaprepitant—Oedema—Triamcinolone—ankylosing spondylitis	0.00226	0.00226	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.00226	0.00226	CcSEcCtD
Fosaprepitant—Syncope—Betamethasone—ankylosing spondylitis	0.00226	0.00226	CcSEcCtD
Fosaprepitant—Syncope—Dexamethasone—ankylosing spondylitis	0.00226	0.00226	CcSEcCtD
Fosaprepitant—Infection—Triamcinolone—ankylosing spondylitis	0.00225	0.00225	CcSEcCtD
Fosaprepitant—Infection—Methylprednisolone—ankylosing spondylitis	0.00225	0.00225	CcSEcCtD
Fosaprepitant—Haematuria—Methotrexate—ankylosing spondylitis	0.00224	0.00224	CcSEcCtD
Fosaprepitant—Shock—Triamcinolone—ankylosing spondylitis	0.00223	0.00223	CcSEcCtD
Fosaprepitant—Insomnia—Prednisolone—ankylosing spondylitis	0.00223	0.00223	CcSEcCtD
Fosaprepitant—Shock—Methylprednisolone—ankylosing spondylitis	0.00222	0.00222	CcSEcCtD
Fosaprepitant—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.00222	0.00222	CcSEcCtD
Fosaprepitant—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.00221	0.00221	CcSEcCtD
Fosaprepitant—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.00221	0.00221	CcSEcCtD
Fosaprepitant—Mental disorder—Prednisone—ankylosing spondylitis	0.00221	0.00221	CcSEcCtD
Fosaprepitant—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.00219	0.00219	CcSEcCtD
Fosaprepitant—Malnutrition—Prednisone—ankylosing spondylitis	0.00219	0.00219	CcSEcCtD
Fosaprepitant—Erythema—Prednisone—ankylosing spondylitis	0.00219	0.00219	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.00219	0.00219	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.00218	0.00218	CcSEcCtD
Fosaprepitant—Hypertension—Dexamethasone—ankylosing spondylitis	0.00217	0.00217	CcSEcCtD
Fosaprepitant—Hypertension—Betamethasone—ankylosing spondylitis	0.00217	0.00217	CcSEcCtD
Fosaprepitant—Anxiety—Dexamethasone—ankylosing spondylitis	0.00214	0.00214	CcSEcCtD
Fosaprepitant—Anxiety—Betamethasone—ankylosing spondylitis	0.00214	0.00214	CcSEcCtD
Fosaprepitant—Discomfort—Dexamethasone—ankylosing spondylitis	0.00212	0.00212	CcSEcCtD
Fosaprepitant—Discomfort—Betamethasone—ankylosing spondylitis	0.00212	0.00212	CcSEcCtD
Fosaprepitant—Hypotension—Methylprednisolone—ankylosing spondylitis	0.00211	0.00211	CcSEcCtD
Fosaprepitant—Pain—Prednisolone—ankylosing spondylitis	0.00211	0.00211	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.00208	0.00208	CcSEcCtD
Fosaprepitant—Urethral disorder—Methotrexate—ankylosing spondylitis	0.00206	0.00206	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.00206	0.00206	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.00206	0.00206	CcSEcCtD
Fosaprepitant—Oedema—Betamethasone—ankylosing spondylitis	0.00206	0.00206	CcSEcCtD
Fosaprepitant—Oedema—Dexamethasone—ankylosing spondylitis	0.00206	0.00206	CcSEcCtD
Fosaprepitant—Insomnia—Triamcinolone—ankylosing spondylitis	0.00205	0.00205	CcSEcCtD
Fosaprepitant—Insomnia—Methylprednisolone—ankylosing spondylitis	0.00204	0.00204	CcSEcCtD
Fosaprepitant—Infection—Betamethasone—ankylosing spondylitis	0.00204	0.00204	CcSEcCtD
Fosaprepitant—Infection—Dexamethasone—ankylosing spondylitis	0.00204	0.00204	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.00203	0.00203	CcSEcCtD
Fosaprepitant—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.00203	0.00203	CcSEcCtD
Fosaprepitant—Anaemia—Prednisone—ankylosing spondylitis	0.00203	0.00203	CcSEcCtD
Fosaprepitant—Shock—Dexamethasone—ankylosing spondylitis	0.00202	0.00202	CcSEcCtD
Fosaprepitant—Shock—Betamethasone—ankylosing spondylitis	0.00202	0.00202	CcSEcCtD
Fosaprepitant—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.00202	0.00202	CcSEcCtD
Fosaprepitant—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.00202	0.00202	CcSEcCtD
Fosaprepitant—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.00202	0.00202	CcSEcCtD
Fosaprepitant—Angioedema—Prednisone—ankylosing spondylitis	0.002	0.002	CcSEcCtD
Fosaprepitant—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.00199	0.00199	CcSEcCtD
Fosaprepitant—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.00199	0.00199	CcSEcCtD
Fosaprepitant—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.00199	0.00199	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.00199	0.00199	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.00199	0.00199	CcSEcCtD
Fosaprepitant—Malaise—Prednisone—ankylosing spondylitis	0.00198	0.00198	CcSEcCtD
Fosaprepitant—Eye disorder—Methotrexate—ankylosing spondylitis	0.00197	0.00197	CcSEcCtD
Fosaprepitant—Syncope—Prednisone—ankylosing spondylitis	0.00197	0.00197	CcSEcCtD
Fosaprepitant—Tinnitus—Methotrexate—ankylosing spondylitis	0.00196	0.00196	CcSEcCtD
Fosaprepitant—Urticaria—Prednisolone—ankylosing spondylitis	0.00196	0.00196	CcSEcCtD
Fosaprepitant—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.00195	0.00195	CcSEcCtD
Fosaprepitant—Fatigue—Triamcinolone—ankylosing spondylitis	0.00195	0.00195	CcSEcCtD
Fosaprepitant—Fatigue—Methylprednisolone—ankylosing spondylitis	0.00195	0.00195	CcSEcCtD
Fosaprepitant—Pain—Triamcinolone—ankylosing spondylitis	0.00194	0.00194	CcSEcCtD
Fosaprepitant—Loss of consciousness—Prednisone—ankylosing spondylitis	0.00193	0.00193	CcSEcCtD
Fosaprepitant—Hypotension—Betamethasone—ankylosing spondylitis	0.00192	0.00192	CcSEcCtD
Fosaprepitant—Hypotension—Dexamethasone—ankylosing spondylitis	0.00192	0.00192	CcSEcCtD
Fosaprepitant—Angiopathy—Methotrexate—ankylosing spondylitis	0.00191	0.00191	CcSEcCtD
Fosaprepitant—Immune system disorder—Methotrexate—ankylosing spondylitis	0.0019	0.0019	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.0019	0.0019	CcSEcCtD
Fosaprepitant—Hypertension—Prednisone—ankylosing spondylitis	0.00189	0.00189	CcSEcCtD
Fosaprepitant—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.00187	0.00187	CcSEcCtD
Fosaprepitant—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.00186	0.00186	CcSEcCtD
Fosaprepitant—Anxiety—Prednisone—ankylosing spondylitis	0.00186	0.00186	CcSEcCtD
Fosaprepitant—Insomnia—Dexamethasone—ankylosing spondylitis	0.00186	0.00186	CcSEcCtD
Fosaprepitant—Insomnia—Betamethasone—ankylosing spondylitis	0.00186	0.00186	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.00185	0.00185	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.00185	0.00185	CcSEcCtD
Fosaprepitant—Discomfort—Prednisone—ankylosing spondylitis	0.00184	0.00184	CcSEcCtD
Fosaprepitant—Mental disorder—Methotrexate—ankylosing spondylitis	0.00184	0.00184	CcSEcCtD
Fosaprepitant—Malnutrition—Methotrexate—ankylosing spondylitis	0.00183	0.00183	CcSEcCtD
Fosaprepitant—Erythema—Methotrexate—ankylosing spondylitis	0.00183	0.00183	CcSEcCtD
Fosaprepitant—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.00181	0.00181	CcSEcCtD
Fosaprepitant—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.00181	0.00181	CcSEcCtD
Fosaprepitant—Dyspepsia—Betamethasone—ankylosing spondylitis	0.00181	0.00181	CcSEcCtD
Fosaprepitant—Urticaria—Triamcinolone—ankylosing spondylitis	0.0018	0.0018	CcSEcCtD
Fosaprepitant—Urticaria—Methylprednisolone—ankylosing spondylitis	0.0018	0.0018	CcSEcCtD
Fosaprepitant—Dysgeusia—Methotrexate—ankylosing spondylitis	0.00179	0.00179	CcSEcCtD
Fosaprepitant—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.00179	0.00179	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.00179	0.00179	CcSEcCtD
Fosaprepitant—Oedema—Prednisone—ankylosing spondylitis	0.00179	0.00179	CcSEcCtD
Fosaprepitant—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.00179	0.00179	CcSEcCtD
Fosaprepitant—Decreased appetite—Betamethasone—ankylosing spondylitis	0.00179	0.00179	CcSEcCtD
Fosaprepitant—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.00179	0.00179	CcSEcCtD
Fosaprepitant—Infection—Prednisone—ankylosing spondylitis	0.00178	0.00178	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.00177	0.00177	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.00177	0.00177	CcSEcCtD
Fosaprepitant—Fatigue—Dexamethasone—ankylosing spondylitis	0.00177	0.00177	CcSEcCtD
Fosaprepitant—Fatigue—Betamethasone—ankylosing spondylitis	0.00177	0.00177	CcSEcCtD
Fosaprepitant—Shock—Prednisone—ankylosing spondylitis	0.00176	0.00176	CcSEcCtD
Fosaprepitant—Pain—Dexamethasone—ankylosing spondylitis	0.00176	0.00176	CcSEcCtD
Fosaprepitant—Pain—Betamethasone—ankylosing spondylitis	0.00176	0.00176	CcSEcCtD
Fosaprepitant—Nervous system disorder—Prednisone—ankylosing spondylitis	0.00176	0.00176	CcSEcCtD
Fosaprepitant—Skin disorder—Prednisone—ankylosing spondylitis	0.00174	0.00174	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.00173	0.00173	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Methotrexate—ankylosing spondylitis	0.0017	0.0017	CcSEcCtD
Fosaprepitant—Anaemia—Methotrexate—ankylosing spondylitis	0.00169	0.00169	CcSEcCtD
Fosaprepitant—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.00169	0.00169	CcSEcCtD
Fosaprepitant—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.00169	0.00169	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.00168	0.00168	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.00168	0.00168	CcSEcCtD
Fosaprepitant—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.00167	0.00167	CcSEcCtD
Fosaprepitant—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.00166	0.00166	CcSEcCtD
Fosaprepitant—Malaise—Methotrexate—ankylosing spondylitis	0.00165	0.00165	CcSEcCtD
Fosaprepitant—Urticaria—Dexamethasone—ankylosing spondylitis	0.00163	0.00163	CcSEcCtD
Fosaprepitant—Urticaria—Betamethasone—ankylosing spondylitis	0.00163	0.00163	CcSEcCtD
Fosaprepitant—Dizziness—Prednisolone—ankylosing spondylitis	0.00163	0.00163	CcSEcCtD
Fosaprepitant—Asthenia—Triamcinolone—ankylosing spondylitis	0.00162	0.00162	CcSEcCtD
Fosaprepitant—Abdominal pain—Betamethasone—ankylosing spondylitis	0.00162	0.00162	CcSEcCtD
Fosaprepitant—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.00162	0.00162	CcSEcCtD
Fosaprepitant—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.00162	0.00162	CcSEcCtD
Fosaprepitant—Body temperature increased—Betamethasone—ankylosing spondylitis	0.00162	0.00162	CcSEcCtD
Fosaprepitant—Asthenia—Methylprednisolone—ankylosing spondylitis	0.00162	0.00162	CcSEcCtD
Fosaprepitant—Insomnia—Prednisone—ankylosing spondylitis	0.00162	0.00162	CcSEcCtD
Fosaprepitant—Pruritus—Triamcinolone—ankylosing spondylitis	0.0016	0.0016	CcSEcCtD
Fosaprepitant—Cough—Methotrexate—ankylosing spondylitis	0.0016	0.0016	CcSEcCtD
Fosaprepitant—Pruritus—Methylprednisolone—ankylosing spondylitis	0.0016	0.0016	CcSEcCtD
Fosaprepitant—Dyspepsia—Prednisone—ankylosing spondylitis	0.00158	0.00158	CcSEcCtD
Fosaprepitant—Chest pain—Methotrexate—ankylosing spondylitis	0.00156	0.00156	CcSEcCtD
Fosaprepitant—Decreased appetite—Prednisone—ankylosing spondylitis	0.00156	0.00156	CcSEcCtD
Fosaprepitant—Rash—Prednisolone—ankylosing spondylitis	0.00155	0.00155	CcSEcCtD
Fosaprepitant—Dermatitis—Prednisolone—ankylosing spondylitis	0.00155	0.00155	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.00155	0.00155	CcSEcCtD
Fosaprepitant—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.00155	0.00155	CcSEcCtD
Fosaprepitant—Fatigue—Prednisone—ankylosing spondylitis	0.00154	0.00154	CcSEcCtD
Fosaprepitant—Headache—Prednisolone—ankylosing spondylitis	0.00154	0.00154	CcSEcCtD
Fosaprepitant—Discomfort—Methotrexate—ankylosing spondylitis	0.00154	0.00154	CcSEcCtD
Fosaprepitant—Constipation—Prednisone—ankylosing spondylitis	0.00153	0.00153	CcSEcCtD
Fosaprepitant—Dizziness—Triamcinolone—ankylosing spondylitis	0.0015	0.0015	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.0015	0.0015	CcSEcCtD
Fosaprepitant—Dizziness—Methylprednisolone—ankylosing spondylitis	0.00149	0.00149	CcSEcCtD
Fosaprepitant—Infection—Methotrexate—ankylosing spondylitis	0.00149	0.00149	CcSEcCtD
Fosaprepitant—Feeling abnormal—Prednisone—ankylosing spondylitis	0.00147	0.00147	CcSEcCtD
Fosaprepitant—Asthenia—Dexamethasone—ankylosing spondylitis	0.00147	0.00147	CcSEcCtD
Fosaprepitant—Asthenia—Betamethasone—ankylosing spondylitis	0.00147	0.00147	CcSEcCtD
Fosaprepitant—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.00147	0.00147	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.00146	0.00146	CcSEcCtD
Fosaprepitant—Nausea—Prednisolone—ankylosing spondylitis	0.00146	0.00146	CcSEcCtD
Fosaprepitant—Pruritus—Betamethasone—ankylosing spondylitis	0.00145	0.00145	CcSEcCtD
Fosaprepitant—Pruritus—Dexamethasone—ankylosing spondylitis	0.00145	0.00145	CcSEcCtD
Fosaprepitant—Skin disorder—Methotrexate—ankylosing spondylitis	0.00145	0.00145	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.00145	0.00145	CcSEcCtD
Fosaprepitant—Vomiting—Triamcinolone—ankylosing spondylitis	0.00144	0.00144	CcSEcCtD
Fosaprepitant—Vomiting—Methylprednisolone—ankylosing spondylitis	0.00144	0.00144	CcSEcCtD
Fosaprepitant—Rash—Triamcinolone—ankylosing spondylitis	0.00143	0.00143	CcSEcCtD
Fosaprepitant—Dermatitis—Triamcinolone—ankylosing spondylitis	0.00143	0.00143	CcSEcCtD
Fosaprepitant—Rash—Methylprednisolone—ankylosing spondylitis	0.00142	0.00142	CcSEcCtD
Fosaprepitant—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.00142	0.00142	CcSEcCtD
Fosaprepitant—Urticaria—Prednisone—ankylosing spondylitis	0.00142	0.00142	CcSEcCtD
Fosaprepitant—Headache—Triamcinolone—ankylosing spondylitis	0.00142	0.00142	CcSEcCtD
Fosaprepitant—Headache—Methylprednisolone—ankylosing spondylitis	0.00142	0.00142	CcSEcCtD
Fosaprepitant—Abdominal pain—Prednisone—ankylosing spondylitis	0.00141	0.00141	CcSEcCtD
Fosaprepitant—Body temperature increased—Prednisone—ankylosing spondylitis	0.00141	0.00141	CcSEcCtD
Fosaprepitant—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.00141	0.00141	CcSEcCtD
Fosaprepitant—Diarrhoea—Betamethasone—ankylosing spondylitis	0.00141	0.00141	CcSEcCtD
Fosaprepitant—Hypotension—Methotrexate—ankylosing spondylitis	0.0014	0.0014	CcSEcCtD
Fosaprepitant—Dizziness—Dexamethasone—ankylosing spondylitis	0.00136	0.00136	CcSEcCtD
Fosaprepitant—Dizziness—Betamethasone—ankylosing spondylitis	0.00136	0.00136	CcSEcCtD
Fosaprepitant—Insomnia—Methotrexate—ankylosing spondylitis	0.00135	0.00135	CcSEcCtD
Fosaprepitant—Nausea—Triamcinolone—ankylosing spondylitis	0.00135	0.00135	CcSEcCtD
Fosaprepitant—Nausea—Methylprednisolone—ankylosing spondylitis	0.00134	0.00134	CcSEcCtD
Fosaprepitant—Dyspnoea—Methotrexate—ankylosing spondylitis	0.00133	0.00133	CcSEcCtD
Fosaprepitant—Somnolence—Methotrexate—ankylosing spondylitis	0.00133	0.00133	CcSEcCtD
Fosaprepitant—Hypersensitivity—Prednisone—ankylosing spondylitis	0.00132	0.00132	CcSEcCtD
Fosaprepitant—Dyspepsia—Methotrexate—ankylosing spondylitis	0.00132	0.00132	CcSEcCtD
Fosaprepitant—Vomiting—Betamethasone—ankylosing spondylitis	0.00131	0.00131	CcSEcCtD
Fosaprepitant—Vomiting—Dexamethasone—ankylosing spondylitis	0.00131	0.00131	CcSEcCtD
Fosaprepitant—Decreased appetite—Methotrexate—ankylosing spondylitis	0.0013	0.0013	CcSEcCtD
Fosaprepitant—Rash—Dexamethasone—ankylosing spondylitis	0.0013	0.0013	CcSEcCtD
Fosaprepitant—Rash—Betamethasone—ankylosing spondylitis	0.0013	0.0013	CcSEcCtD
Fosaprepitant—Dermatitis—Betamethasone—ankylosing spondylitis	0.00129	0.00129	CcSEcCtD
Fosaprepitant—Dermatitis—Dexamethasone—ankylosing spondylitis	0.00129	0.00129	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.00129	0.00129	CcSEcCtD
Fosaprepitant—Fatigue—Methotrexate—ankylosing spondylitis	0.00129	0.00129	CcSEcCtD
Fosaprepitant—Headache—Dexamethasone—ankylosing spondylitis	0.00129	0.00129	CcSEcCtD
Fosaprepitant—Headache—Betamethasone—ankylosing spondylitis	0.00129	0.00129	CcSEcCtD
Fosaprepitant—Asthenia—Prednisone—ankylosing spondylitis	0.00128	0.00128	CcSEcCtD
Fosaprepitant—Pain—Methotrexate—ankylosing spondylitis	0.00128	0.00128	CcSEcCtD
Fosaprepitant—Pruritus—Prednisone—ankylosing spondylitis	0.00127	0.00127	CcSEcCtD
Fosaprepitant—Feeling abnormal—Methotrexate—ankylosing spondylitis	0.00123	0.00123	CcSEcCtD
Fosaprepitant—Diarrhoea—Prednisone—ankylosing spondylitis	0.00122	0.00122	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.00122	0.00122	CcSEcCtD
Fosaprepitant—Nausea—Dexamethasone—ankylosing spondylitis	0.00122	0.00122	CcSEcCtD
Fosaprepitant—Nausea—Betamethasone—ankylosing spondylitis	0.00122	0.00122	CcSEcCtD
Fosaprepitant—Urticaria—Methotrexate—ankylosing spondylitis	0.00119	0.00119	CcSEcCtD
Fosaprepitant—Dizziness—Prednisone—ankylosing spondylitis	0.00118	0.00118	CcSEcCtD
Fosaprepitant—Body temperature increased—Methotrexate—ankylosing spondylitis	0.00118	0.00118	CcSEcCtD
Fosaprepitant—Abdominal pain—Methotrexate—ankylosing spondylitis	0.00118	0.00118	CcSEcCtD
Fosaprepitant—Vomiting—Prednisone—ankylosing spondylitis	0.00114	0.00114	CcSEcCtD
Fosaprepitant—Rash—Prednisone—ankylosing spondylitis	0.00113	0.00113	CcSEcCtD
Fosaprepitant—Dermatitis—Prednisone—ankylosing spondylitis	0.00113	0.00113	CcSEcCtD
Fosaprepitant—Headache—Prednisone—ankylosing spondylitis	0.00112	0.00112	CcSEcCtD
Fosaprepitant—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.0011	0.0011	CcSEcCtD
Fosaprepitant—Asthenia—Methotrexate—ankylosing spondylitis	0.00107	0.00107	CcSEcCtD
Fosaprepitant—Nausea—Prednisone—ankylosing spondylitis	0.00106	0.00106	CcSEcCtD
Fosaprepitant—Pruritus—Methotrexate—ankylosing spondylitis	0.00106	0.00106	CcSEcCtD
Fosaprepitant—Diarrhoea—Methotrexate—ankylosing spondylitis	0.00102	0.00102	CcSEcCtD
Fosaprepitant—Dizziness—Methotrexate—ankylosing spondylitis	0.000989	0.000989	CcSEcCtD
Fosaprepitant—Vomiting—Methotrexate—ankylosing spondylitis	0.000951	0.000951	CcSEcCtD
Fosaprepitant—Rash—Methotrexate—ankylosing spondylitis	0.000943	0.000943	CcSEcCtD
Fosaprepitant—Dermatitis—Methotrexate—ankylosing spondylitis	0.000942	0.000942	CcSEcCtD
Fosaprepitant—Headache—Methotrexate—ankylosing spondylitis	0.000937	0.000937	CcSEcCtD
Fosaprepitant—Nausea—Methotrexate—ankylosing spondylitis	0.000888	0.000888	CcSEcCtD
